Methadyl Acetate is a narcotic analgesic with a long onset and duration of action. Methadyl Acetate is primarily a mu-type opioid receptor agonist and the drug decreases a patient's opioid use by preventing opioid withdrawal. Levacetylmethadol, the enantiomer of Methadyl Acetate, was approved in 1993 by the U.S. Food and Drug Administration for use in the treatment of opioid dependence. In 2001, levacetylmethadol was removed from the U.S. market due to reports of life-threatening ventricular rhythm disorders.

Fluprednidene (used in a form of fluprednidene 21-acetate) is a glucocorticoid developed for the treatment of inflammatory skin diseases. The drug is marketed under the name Decoderm in Europe.

Chloroprednisone acetate is the 21-acetate ester of chloroprednisone. Chloroprednisone acetate was sold under the brand name Topilan as an anti-inflammatory agent.

Cyproterone belongs to a group of medications known as steroidal antiandrogens. It suppresses testosterone and its metabolites. It has approximately three-fold lower potency as an antagonist of the androgen receptor relative to cyproterone acetate. Cyproterone acetate is used to treat advanced prostate cancer and acne.

Anagestone acetate is a progestin medication, used in the 1960s in combination with the estrogen mestranol as a combined birth control pill. Toxicological study of chronic administration in dogs and monkeys showed the increased risk of developing malignant tumors in the mammary glands and a dose-dependent, nonprogressive decrease in hemoglobin and hematocrits. The drug was voluntarily withdrawn from the market in 1969.

Elliptinium is an antineoplastic agent, which was used in the treatment of metastatic breast cancer in France under the name Celiptium. The drug is known to intercalate into DNA and inhibit topoisomerase II. Several studies have demonstrated that this molecule can be oxidized, yielding a reactive electrophilic form, which is able to bind covalently to a nucleophilic biological molecule.

Beryllium is a chemical element in the periodic table that has the symbol Be and atomic number 4. A toxic bivalent element, beryllium is a steel grey, strong, light-weight yet brittle, alkaline earth metal. Beryllium is an ubiquitous element in the environment, and it has many commercial applications. Beryllium is used in alloys with copper or nickel to make gyroscopes, springs, electrical contacts, spot-welding electrodes and non-sparking tools. Mixing beryllium with these metals increases their electrical and thermal conductivity. Other beryllium alloys are used as structural materials for high-speed aircraft, missiles, spacecraft and communication satellites. Beryllium is relatively transparent to X-rays so ultra-thin beryllium foil is finding use in X-ray lithography. Beryllium is also used in nuclear reactors as a reflector or moderator of neutrons. Beryllium and its compounds are toxic and carcinogenic. If beryllium dust or fumes are inhaled, it can lead to an incurable inflammation of the lungs called berylliosis. Because it is strong, stable, can handle elevated levels of heat resistance and is highly transparent to x-rays, beryllium, in thin foil form, has long been critical to the operation of medical and scientific x-ray equipment. Beryllium foil provides the window through which tissue-penetrating x-rays are focused, while maintaining the vacuum inside the x-ray tube generator. Beryllium foil remains indispensible for high-resolution medical radiography, including CT scanning and mammography. Beryllium in newer generation mammography equipment enables a lower radiation dose scan with significantly finer tumor resolution, enabling breast cancer detection at its early, most treatable stages. Beryllium is also used in components of the analytical equipment used to analyze blood for HIV and other diseases, offering the precision and reliability that doctors and patients demand.

Nomegestrol acetate (NOMAC) is a 19-norprogesterone derivative with high biological activity at the progesterone receptor, a weak anti-androgenic effect, but with no binding to estrogen, glucocorticoid or mineralocorticoid receptors. Nomegestrol has been developed by the Monaco-based company Théramex SAM (a Teva subsidiary). Nomegestrol acetate has been used successfully for the treatment of some gynaecological disorders (menstrual disturbances, dysmenorrhoea, premenstrual syndrome) and as a component of hormone replacement therapy in combination with estradiol for the relief of menopausal symptoms; it has been approved in Europe as monotherapy for the treatment of the menopausal syndrome, uterine diseases and menorrhagia, and in combination with an estrogen for the treatment of menopausal symptoms. Nomegestrol acetate in combination with estradiol is used as an oral contraceptive.

Dequalinium is a quaternary ammonium cation commonly available as the dichloride salt. Dequalinium chloride has an antiseptic effect against a wide range of bacteria, yeasts, and some fungi and viruses. It kills the micro-organisms associated with various mild infections of the mouth and throat. Also, Dequalinium chloride is active against the bacteria which cause bacterial vaginosis. Dequalinium Chloride (DECA) is a PKC inhibitor and high-affinity blocker CNGA1 channel, and nearly as effective on heteromeric CNGA1+CNGB1 channels. Common side effects are: vaginal discharge; vaginal itching or vaginal burning; vaginal yeast infection (thrush); tender tongue.

Cyproterone acetate is a steroid drug which was developed by Schering A.G (now Bayer). Cyproterone acetate was approved in Canada, Asia, Latin America and Europe for the treatment of sever acne under the name Diane-35 (ethinyl estradiol) and its mechanism of action in this condition is explained by competitive inhibition of androgen receptor AR. In Canada cyproterone acetate is widely used as a contraceptive, however its usage is associated with liver toxicity and clots formation. In the UK the drug is marketed for the treatment of prostate cancer (Cyproterone acetate brand name).